Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
N/A
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Zepbound (tirzepatide) is a once-weekly injectable medicine approved by the FDA, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction in adults with obesity or overweight with at least one weight-related condition, and to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
Zepbound is a dual GIP and GLP-1 receptor agonist. By activating both of these gut hormone receptors, it helps reduce appetite and food intake, slow gastric emptying, and improve metabolic signaling, leading to significant weight reduction in clinical studies.
Zepbound is intended for adults with obesity, or overweight with at least one weight-related comorbid condition, seeking chronic weight management, as well as adults with obesity and moderate to severe obstructive sleep apnea. Note: Zepbound shares the same active ingredient as Mounjaro, which is approved for a different indication — type 2 diabetes.
Zepbound is started at 2.5 mg subcutaneously once weekly for 4 weeks, then increased in 2.5 mg increments at intervals of at least 4 weeks based on response and tolerability, up to a maintenance dose of 5 mg to 15 mg once weekly.
Boxed Warning — Zepbound: In studies with rodents, tirzepatide caused thyroid C-cell tumors. It is unknown whether Zepbound causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Zepbound is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Severe gastrointestinal adverse reactions have been reported, which in some cases have led to acute kidney injury or worsening of chronic kidney disease due to volume depletion.
Acute pancreatitis and acute gallbladder disease have been reported. Zepbound should be discontinued if pancreatitis is suspected.
The risk of hypoglycemia is increased when Zepbound is used with insulin or insulin secretagogues. Patients with a history of diabetic retinopathy should be monitored for progression.
Zepbound delays gastric emptying and may increase the risk of pulmonary aspiration during procedures requiring anesthesia or deep sedation. Serious hypersensitivity reactions have also been reported.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Zepbound is manufactured and marketed by Eli Lilly and Company. It is sourced through authorized distribution channels for patients seeking named-patient import into India. Note: the same active ingredient, tirzepatide, is also marketed by Eli Lilly under the brand Mounjaro for type 2 diabetes — a different approved indication.
Patients typically need a valid prescription from a treating physician confirming obesity/overweight diagnosis with a qualifying weight-related condition, or obstructive sleep apnea diagnosis. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved therapy for chronic weight management and OSA, Zepbound is sourced through authorized channels and imported under GDP-compliant, cold-chain logistics to preserve product quality throughout transit.
NPP sources Zepbound directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Zepbound requires refrigerated storage at 2°C to 8°C; it may be kept at up to 25°C for a maximum of 30 days if needed. NPP maintains a continuous, monitored cold chain throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile cold-chain logistics to the patient's city.
Patients across India can access Zepbound through NPP's regulated import pathway, with weight management and endocrinology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support weight management care coordination and documentation for Zepbound access.
Delhi's major hospitals assist patients with prescription support and documentation for Zepbound.
Bangalore's specialist network offers access coordination for eligible patients seeking Zepbound.
Chennai-based endocrinology specialists coordinate Zepbound access alongside comprehensive weight management care.
Hyderabad's care institutions support patients pursuing Zepbound therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Zepbound.
Pune-based specialists assist with prescription support and Zepbound treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Zepbound.
Kochi's specialist units assist patients with the documentation needed for Zepbound access.
Chandigarh's care centers support Zepbound treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Zepbound access process.
Lucknow-based centers assist patients pursuing Zepbound therapy.
Bhubaneswar's institutions support access to Zepbound for eligible patients.
Guwahati's specialists help coordinate Zepbound access for patients across the Northeast.
Patients in other cities across India can also access Zepbound through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 15 September 2026
Sources: FDA
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
